Navigation Links
RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
Date:1/14/2014

WESTBOROUGH, Mass., Jan. 14, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI-109, for the treatment of fibrotic disorders. The patent, once issued, will be scheduled to expire in 2029.

"This notice of allowance from the USPTO is of high importance for RXi's Intellectual Property position in the RNAi field, and more specifically in the space of skin and organ fibrosis," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Our sd-rxRNA compound, RXI-109 targeting CTGF, has already demonstrated excellent safety results in our Phase 1 trials and has confirmed the mechanism of action of this self-delivering RNAi in humans in a dose dependent manner. This patent enhances our ability to broadly protect our proprietary technology, including our anti-fibrotic compounds, reinforcing the potential for future commercial and business development opportunities."

About RXI-109

RXi Pharmaceuticals' first clinical program involves RXI‑109, a self-delivering RNAi compound (sd‑rxRNA®) developed for the reduction of dermal scarring. RXI‑109 is designed to reduce the expression of CTGF, a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin. The first clinical trials with RXI‑109 showed excellent safety and tolerability with ascending single and multiple doses, as well as dose dependent effects on the Connective Tissue Growth Factor protein an
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 26, 2014 The report ... defines and segments the concerned market for revenue forecasts ... at a CAGR of 51.9% from 2013 to 2018. ... reach a value of $1,415.6 million by 2018. , ... Automation Report TOC for information about the market segmentation ...
(Date:11/26/2014)... The announced sales of three healthcare units ... to expand in non-healthcare areas, says Kalorama Information. Siemens ... firm says that  Siemens is the third largest company ... the IVD market , with 5.5 billion in IVD ... would likely affect IVD market shares.  ...
(Date:11/26/2014)... The ETC (Emerging Technology Centers) ... centers, announced today that applications for AccelerateBaltimore™ (AB) ... “Do you have a big idea?,” asked ETC’s ... know about it. AccelerateBaltimore helps you and your ... just 13 weeks.” Interested game changers with ...
(Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) ... Alliance , provider of clinical research and data management ... addition to its CRO Partnership Program, Clinovo expands ... India. , “We have found Clinovo’s ClinCapture to ... platform which is both user friendly and easy to ...
Breaking Biology Technology:Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2
... 2011 China PharmaHub Corp. (OTC Bulletin Board: ... today announced that it has signed a exclusive worldwide ... rights to develop, commercialize and market a universal donor ... UCSD Associate Professor of Medicine and Pediatrics Dr. Ewa ...
... FREMONT, Calif. and SAN CARLOS, Calif., March 21, ... WGBS ), a leading developer of ... a leader in innovative genomic samples preparation, today ... integrated workflows for gene expression profiling and target ...
... N.J., March 21, 2011 Intrasphere Technologies ( ... solutions firm that provides services to Life Sciences ... SafetyXpress for Argus is Intrasphere,s proprietary implementation accelerator ... Safety suite. Intrasphere is a Specialized Oracle Argus ...
Cached Biology Technology:China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 2WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 3WaferGen and NuGEN Announce Agreement to Co-Develop Integrated Workflows Using SmartChip System and SPIA® for Single Cell Analysis, FFPE and Next Generation Sequencing 4Intrasphere Technologies Launches SafetyXpress(TM) for Oracle(R) Argus Safety 2
(Date:11/4/2014)... CORAL GABLES, Fla. (November 4, 2014) — Think about ... and ask: How do neighboring cells know that they ... cell and how do these tissues find the correct ... (UM) are answering these crucial questions. , In a ... tissues use to communicate with their surrounding neighbors, at ...
(Date:11/4/2014)... 2014) – A majority of Madagascar,s 101 species of ... serious consequences for the rainforests they call home. A ... impacts lemurs can have on rainforest tree populations, which ... have on the region,s rich biodiversity. , A large ... by lemurs. Lemurs in turn disperse the seeds ...
(Date:11/3/2014)... University of Colorado Cancer Center study published ... of Sciences describes the activity of a recently ... 37 or IL-37. It has been known to limit ... the adaptive immune system: IL-37 inhibits the ability of ... , "Knowing this mechanism that underlies IL-37,s effect on ...
Breaking Biology News(10 mins):The inside story: How the brain and skull stay together 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... Scientists at Cold Spring Harbor Laboratory (CSHL) and ... implying that commonly occurring large chromosomal deletions that ... multiple functionally linked genes whose loss, they posit, confers ... Looking closely at one large deletion -- a so-called ...
... , This press release is available in ... doctors need unique features which they can use to unequivocally ... search for the biomarkers for an illness or a combination ... possible to measure. Researchers at the Max Planck Institute for ...
... with research associate Jerilyn Walker and assistant professor Miriam Konkel, ... ancient jumping genes called Alu, which are more than 16 ... the Zoological Society of San Diego and the Institute of ... open access journal Mobile DNA . These tiny ...
Cached Biology News:Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers 2Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers 3Biosignatures distinguish between tuberculosis and sarcoidosis 2Biosignatures distinguish between tuberculosis and sarcoidosis 3LSU research finds orangutans host ancient jumping genes 2
Rabbit Serum New Zealand or California Origin...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
... Synthesis , Containing one Phospho-Amino Acid , ... customer conjugation of peptide to KLH protein , Rabbits ... , Pre-immune bleed x1 /each , ... bleed (app. 5 ml) x1 /each , ...
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
Biology Products: